Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells

Amy Kimball, MD, PhD, Mehmet Burcu, BS, Kieran L O’Loughlin, MS, Laurie A. Ford, Hans Minderman, Maria Baer

Blood (2008) 112 (11): 5021.

https://doi.org/10.1182/blood.V112.11.5021.5021

Published: 2008

Journal Articles

Randomized Trial of GM-CSF and G-CSF Following High-Dose Cytarabine and Mitoxantrone Chemotherapy for Relapsed and Refractory Acute Leukemia.

Maria R. Baer, MD, Laurie A. Ford, BS, Brian N. Bundy, PhD, Sheila M. Tighe, BS, Kieran L. O’Loughlin, MS, James L. Slack, MD, Meir Wetzler, MD, Paul K. Wallace, PhD

Blood (2006) 108 (11): 4574.

https://doi.org/10.1182/blood.V108.11.4574.4574

Published: 2006

Journal Articles

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Michael A. Caligiuri, MD, Ben L. Sanford, MS, Kieran L. O’Loughlin, MS, Krysztof Mrozek, PhD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2006) 108 (11): 424.

https://doi.org/10.1182/blood.V108.11.424.424

Published: 2006

Journal Articles

The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.

Attaphol Pawarode, MD, Kieran L. O’Loughlin, MS, Nicholas W. Cuviello, William R. Greco, PhD, Laurie A. Ford, BS, Hans Minderman, PhD, Maria R. Baer, MD

Blood (2005) 106 (11): 1512.

https://doi.org/10.1182/blood.V106.11.1512.1512

Published: 2005

Journal Articles

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

Misbah Qadir, MD, Kieran L. O’Loughlin, MS, Nicole A. Williamson, BA, Hans Minderman, PhD, Maria R. Baer, MD

Blood (2004) 104 (11): 1180.

https://doi.org/10.1182/blood.V104.11.1180.1180

Published: 2004

Journal Articles

Acute Myeloid Leukemia Cells Are Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Mechanism Independent of Multidrug Resistance.

Stacy M. Fricke, BS, Hans Minderman, PhD, Kieran L. O’Loughlin, MS, Jinrong Cheng, MS, Elizabeth A. Repasky, PhD, Maria R. Baer, MD

Blood (2004) 104 (11): 4385.

https://doi.org/10.1182/blood.V104.11.4385.4385

Published: 2004

NARROW

Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells

Randomized Trial of GM-CSF and G-CSF Following High-Dose Cytarabine and Mitoxantrone Chemotherapy for Relapsed and Refractory Acute Leukemia.

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

Acute Myeloid Leukemia Cells Are Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Mechanism Independent of Multidrug Resistance.

Email alerts

ASH Publications

American Society of Hematology

Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells

Randomized Trial of GM-CSF and G-CSF Following High-Dose Cytarabine and Mitoxantrone Chemotherapy for Relapsed and Refractory Acute Leukemia.

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.

Cyclosporine A Modulates the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein, Breast Cancer Resistance Protein and Lung Resistance Protein.

Acute Myeloid Leukemia Cells Are Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Mechanism Independent of Multidrug Resistance.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only